Unknown

Dataset Information

0

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials.


ABSTRACT: BACKGROUND:Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy-induced nausea and vomiting (CINV) despite use of antiemetics. APF530 is a sustained-release subcutaneous (SC) formulation of granisetron for preventing CINV. APF530 pharmacokinetics, safety, and efficacy were studied in two open-label, single-dose Phase II trials (C2005-01 and C2007-01, respectively) in patients receiving moderately emetogenic chemotherapy or highly emetogenic chemotherapy. METHODS:In C2005-01, 45 patients received APF530 250, 500, or 750 mg SC (granisetron 5, 10, or 15 mg, respectively). In C2007-01, 35 patients were randomized to APF530 250 or 500 mg SC. Injections were given 30 to 60 minutes before single-day moderately emetogenic chemotherapy or highly emetogenic chemotherapy. Plasma granisetron was measured from predose to 168 hours after study drug administration. Safety and efficacy were also evaluated. RESULTS:APF530 pharmacokinetics were dose proportional, with slow absorption and elimination of granisetron after a single SC dose. Median time to maximum plasma concentration and half-life were similar for APF530 250 and 500 mg in both trials, with no differences between the groups receiving moderately and highly emetogenic chemotherapy. Exposure to granisetron was maintained at a therapeutic level over the delayed-onset phase, at least 168 hours. Adverse events in both trials were as expected for granisetron; injection site reactions (eg, erythema and induration) were predominantly mild and seen in ?20% of patients. Complete responses (no emesis, with no rescue medication) were obtained in the acute, delayed, and overall phases in ?80% and ?75% of patients in both trials with the 250 and 500 mg doses, respectively. CONCLUSION:After a single injection of APF530, there were dose-proportional pharmacokinetics and sustained concentrations of granisetron over 168 hours. The 250 and 500 mg doses were well tolerated and maintained therapeutic granisetron levels for ?5 days.

SUBMITTER: Gabrail N 

PROVIDER: S-EPMC4370683 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4311069 | BioStudies
2016-01-01 | S-EPMC4769519 | BioStudies
2017-01-01 | S-EPMC5446958 | BioStudies
2011-01-01 | S-EPMC3166600 | BioStudies
1000-01-01 | S-EPMC5084806 | BioStudies
2020-01-01 | S-EPMC7085480 | BioStudies
2020-01-01 | S-EPMC6954135 | BioStudies
2019-01-01 | S-EPMC6615793 | BioStudies
2013-01-01 | S-EPMC3804728 | BioStudies
1000-01-01 | S-EPMC5834144 | BioStudies